Glaxo's Arzerra Misses Target in Clinical Trial

World News: . []

GlaxoSmithKline and Genmab said their drug ofatumumab failed to meet its primary endpoint for treating bulky fludarabine-refractory chronic lymphocytic leukemia in a Phase-3 study.

Read More: LINK 

Published: .

Search for other references to "glaxo" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us